Humira access expands

Humira is one of the biggest autoimmune drugs in the U.S., and this week it moved onto the White House’s TrumpRx discount site at a cash price of $950 for a two-count 40 milligram pen pack instead of $6,922.62. CBS News reported the listing went live as AbbVie and Genentech became the 10th and 11th drugmakers on the platform. (cbsnews.com) (trumprx.gov) TrumpRx is built around “most-favored-nation” pricing, which means the administration says uninsured Americans should be offered prices closer to what drugmakers accept in other developed countries. Fierce Pharma reported AbbVie’s January 12, 2026 agreement gave the company tariff relief and protection from future pricing mandates in exchange for lower prices and direct-to-patient sales through TrumpRx. (fiercepharma.com) (news.abbvie.com) AbbVie had already named Humira in that January deal, alongside Alphagan, Combigan, and Synthroid, so this week’s change is the public storefront catching up with a policy agreement signed three months earlier. AbbVie said the agreement runs for three years and includes a $100 billion U.S. research and manufacturing pledge over the next decade. (news.abbvie.com) (fiercepharma.com) Humira’s generic name is adalimumab, and it works by blocking tumor necrosis factor, which is an immune-system signal that can keep inflammation switched on like a stuck fire alarm. The Food and Drug Administration label says the drug is used for conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, and uveitis. (accessdata.fda.gov) (humira.com) The patients most likely to notice this first are cash-paying people who were previously staring at a list price near $7,000 per carton. TrumpRx’s own terms say the coupon is for self-paying patients with a valid prescription and cannot be combined with insurance benefits or counted toward deductibles or out-of-pocket maximums. (trumprx.gov) That detail matters because a cheaper cash route can change who shows up in the treated population. CBS News said the current discounts are mainly for people who are uninsured or whose insurance does not cover the drug, which is a different mix from patients getting Humira through commercial plans, Medicare, or Medicaid. (cbsnews.com) (trumprx.gov) Humira is not a simple pill you take without follow-up. The prescribing information carries a boxed warning for serious infections and malignancy, and AbbVie’s professional site says patients should be tested for tuberculosis before starting treatment and monitored for infection during and after use. (accessdata.fda.gov) (humirapro.com) When access expands through a new channel, safety reporting can shift even if the drug itself does not change. A patient who gets a prescription through a cash coupon, fills it at a retail pharmacy, and sees a different doctor or fewer specialists can enter the monitoring system through different doors than a patient managed inside a tightly controlled insurance program, which can change what gets noticed and reported first. (trumprx.gov) (accessdata.fda.gov) There is another layer here: Humira is no longer the untouchable blockbuster it was before patent loss. Fierce Pharma noted that Humira has been declining since losing exclusivity in 2023, so offering an 86% discount on a government-backed cash platform is also a way for AbbVie to defend volume while Washington pushes lower prices. (fiercepharma.com) (trumprx.gov) For now, the clearest facts are simple: as of April 6, 2026, Humira joined TrumpRx, the listed cash price is $950, and the offer is aimed at self-pay patients rather than standard insurance billing. If Congress later changes the rules so government-insured patients can apply copays to TrumpRx purchases, the size and shape of the Humira market could change again. (cbsnews.com) (trumprx.gov)